Comparison 51. HA/hylan versus NSAID.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Pain after walking (0‐100 mm VAS)	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
1.1 1 to 4 weeks post‐injection	2	333	Mean Difference (IV, Random, 95% CI)	3.28 [‐6.45, 13.02]
2 Patient general satisfaction wtih treatment (excellent or good vs satisfactory or bad)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 HA arm versus regular dose celecoxib	1	60	Risk Ratio (M‐H, Fixed, 95% CI)	0.62 [0.46, 0.84]
2.2 HA + low dose celecoxib arm versus regular dose celecoxib	1	60	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.94, 1.13]
2.3 HA + voluntary dose of celecoxib arm versus regular dose of celecoxib	1	60	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.91, 1.10]
3 Safety: total withdrawals overall	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.1 14 to 26 weeks post‐injection	2	392	Risk Ratio (M‐H, Fixed, 95% CI)	1.19 [0.88, 1.61]
3.2 45 to 52 weeks post‐injection	1	216	Risk Ratio (M‐H, Fixed, 95% CI)	1.17 [0.41, 3.37]
4 Safety: number of withdrawals due to inefficacy	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only